Clinical trial examines oral supplementation in age-related macular degeneration
A daily 15 mg dose of the oral medication pazopanib for patients with age-related macular degeneration (AMD, a leading cause of blindness) resulted in improvements in vision and other measures related to the retina, according to a report of two clinical trials by Megan M. McLaughlin, M.S., of GlaxoSmithKline, King of Prussia, Pa., and colleagues...